GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...

“Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® ...

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives.

William Blair initiated coverage on Alcon Inc. (NYSE: ALC) on Friday with a Market Perform rating. Over the past two years, Alcon has been aggressive in driving top-line growth both internally ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...